Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489141 | 0.92 | CCKBR (0.49) | POLBCCKBR | |
| SCHEMBL6492753 | 0.78 | POLB (0.46) | RAB9APOLBPKMMAPTTP53 | |
| SCHEMBL6488303 | 0.78 | TP53 (0.50) | RAB9APOLBPKMMAPTTP53 | |
| SCHEMBL6065051 | 0.76 | CCKBR (0.54) | CCKBR | |
| SCHEMBL6531513 | 0.76 | CCKBR (0.50) | RAB9APOLBPKMKMT2ACCKBR | |
| SCHEMBL6500295 | 0.73 | MAPT (0.48) | RAB9APOLBPKMMAPTTP53 | |
| SCHEMBL6489556 | 0.72 | CCKBR (0.58) | RAB9AKMT2ACCKBRHIF1ANPC1 | |
| SCHEMBL6065554 | 0.72 | CCKBR (0.53) | CCKBR | |
| SCHEMBL6064608 | 0.71 | CCKBR (0.54) | CCKBR | |
| SCHEMBL6065159 | 0.70 | CCKBR (0.53) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956053-B2 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | THE JAMES BLACK FOUNDATION LIMITED (GB) | 2005-10-18 | — | — | US | disclosed |
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | JAMES BLACK FOUNDATION LIMITED, THE (GB) | 2003-11-06 | — | — | US | disclosed |
| WO-2001090078-A1 | PYRAZOLE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKIN IN RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207874-A1 | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | CCKBR, GRPR, CCKAR | RAB9A 1158/4885POLB 4006/4885PKM 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.